Alpha- XXXX modulates ovarian surface epithelial cell growth.

@entity1 @entity32 @entity43 @entity7919 @entity5 @entity19 @entity6223 @entity12837 @entity637
OBJECTIVE: The intracellular redox state plays an important role in controlling @entity32 . Clinical and laboratory data suggest that @entity32 can lead to @entity5 progression. We hypothesized that restoring intracellular redox control would inhibit @entity32 and subsequently @entity5 progression. Our studies were designed to investigate the effect of @entity12837 (ALA), a naturally occurring antioxidant, on a key inflammatory signaling pathway and cell proliferation in normal and tumorigenic ovarian surface epithelial cells. METHODS: Normal and tumorigenic ovarian surface epithelial cells were isolated as described by Roby and coworkers [Roby KF, Taylor CC, @entity6223 , Cheng Y, Pace JL, Tawpik O, @entity1 DL, Smith PG, Terranova PF, Development of a syngeneic @entity19 model for events related to @entity43 . Carcinogen 2000;21 (4):585. [1]]. The effect of ALA on cellular function was measured in cell proliferation and apoptosis assays. @entity7919 ( @entity7919 ) protein levels were measured by Western analysis. Activation of NF-kappaB dependent transcription was assessed in cell cultures transiently transfected with NF-kappaB controlled reporter constructs. RESULTS: Our results reveal that ALA selectively inhibits the growth of tumorigenic as compared to non-tumorigenic ovarian surface epithelial cells. The growth inhibitory effect of ALA is not due to induction of apoptosis but instead is associated with an increase in the half-life of the @entity7919 . In parallel to the growth inhibitory effect, ALA also affects a key inflammatory signaling pathway by inhibiting @entity637 -induced NF-kappaB signaling activity. CONCLUSIONS: Our studies are the first to show that ALA treatment has a growth inhibitory effect on malignant surface epithelial cells of ovarian origin. We have also confirmed the reproducibility of the immunocompetent @entity19 @entity43 model originally described by Roby and coworkers [Roby KF, Taylor CC, @entity6223 , Cheng Y, Pace JL, Tawpik O, @entity1 DL, Smith PG, Terranova PF, Development of a syngeneic @entity19 model for events related to @entity43 . Carcinogen 2000;21 (4):585].
